This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Chair’s Closing Remarks

Chair’s Closing Remarks

6:00 pm - Wednesday 22nd July 2026

Speakers:

Keith Hoffmaster

Global Head, Early Clinical Development Radioligand Therapies

Novartis AG